Post by Sartorius

Sartorius launches Eveo Cell Therapy Platform, a next-generation platform to boost efficiency in cell therapy production 🚀 📈 Up to 4× higher output in existing cleanroom space 💲 Up to 90 percent reduction in manufacturing costs in CAR-T processes 🙌 Successful pilot project with CDMO ElevateBio proves applicability Autologous cell therapies, such as CAR-T therapies, hold enormous potential, yet manufacturing remains complex, difficult to scale and therefore expensive. With the new Eveo Cell Therapy Platform, we are introducing a fundamentally new approach designed to address these structural bottlenecks. Eveo integrates cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed, modular system, while bioanalytical tools address key challenges of quality control. A successful pilot with ElevateBio, a leading therapy CDMO, amongst other partners, demonstrated the platform’s real-world applicability. Due to its multi-parallel configuration, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses – an almost fourfold increase. Financial modelling confirms that the platform can reduce manufacturing costs by around 90 percent. Order placement will begin in September 2026. 🔗 Read the full Media Release: https://ow.ly/9QO250YuI00 🌐 More information about Eveo Cell Therapy Platform: https://ow.ly/FR9L50YuI02 #SimplifyingProgress #CellTherapy #ProductLaunch